Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Medtronic
Merck
AstraZeneca
Express Scripts

Last Updated: November 14, 2019

DrugPatentWatch Database Preview

Eribulin mesylate - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic sources for eribulin mesylate and what is the scope of patent protection?

Eribulin mesylate is the generic ingredient in one branded drug marketed by Eisai Inc and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Eribulin mesylate has seventy-five patent family members in twenty-five countries.

One supplier is listed for this compound.

Summary for eribulin mesylate
International Patents:75
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 21
Clinical Trials: 68
Patent Applications: 7
DailyMed Link:eribulin mesylate at DailyMed
Recent Clinical Trials for eribulin mesylate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Immunomedics, Inc.Phase 3
Big Ten Cancer Research ConsortiumPhase 1
PfizerPhase 1

See all eribulin mesylate clinical trials

Pharmacology for eribulin mesylate
Drug ClassMicrotubule Inhibitor
Physiological EffectMicrotubule Inhibition
Synonyms for eribulin mesylate
441045-17-6
AC-27728
AKOS025401973
AKOS030238218
AV9U0660CW
B-1939
C40H59NO11.CH4O3S
CHEBI:70710
CHEMBL1683544
CS-2803
D08914
E 7389
E7389
Eribulin (mesylate)
Eribulin mesilate
Eribulin mesilate (JAN)
Eribulin mesylate (USAN)
Eribulin mesylate [USAN]
Halaven
Halaven (TN)
HY-13442A
NSC-707389
QAMYWGZHLCQOOJ-WRNBYXCMSA-N
UNII-AV9U0660CW
Y1702
Z-3266

US Patents and Regulatory Information for eribulin mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc HALAVEN eribulin mesylate SOLUTION;INTRAVENOUS 201532-001 Nov 15, 2010 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Eisai Inc HALAVEN eribulin mesylate SOLUTION;INTRAVENOUS 201532-001 Nov 15, 2010 RX Yes Yes   Start Trial   Start Trial   Start Trial
Eisai Inc HALAVEN eribulin mesylate SOLUTION;INTRAVENOUS 201532-001 Nov 15, 2010 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Eisai Inc HALAVEN eribulin mesylate SOLUTION;INTRAVENOUS 201532-001 Nov 15, 2010 RX Yes Yes   Start Trial   Start Trial   Start Trial
Eisai Inc HALAVEN eribulin mesylate SOLUTION;INTRAVENOUS 201532-001 Nov 15, 2010 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for eribulin mesylate

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1087960 91854 Luxembourg   Start Trial 91854, EXPIRES: 20240616
1087960 11C0038 France   Start Trial PRODUCT NAME: ERIBULINE, SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER MESYLATE D'ERIBULINE; REGISTRATION NO/DATE: EU/1/11/678/001 20110317
1087960 CA 2011 00022 Denmark   Start Trial
1087960 2011C/028 Belgium   Start Trial PRODUCT NAME: ERIBULIN; AUTHORISATION NUMBER AND DATE: EU/1/11/678/001 20110317
1087960 1190021-4 Sweden   Start Trial PRODUCT NAME: ERIBULIN OCH FARMACEUTISKT ACCEPTABLA SALTER DAERAV, I SYNNERHET ERIBULINMESYLAT; REG. NO/DATE: EU/1/11/678/001-002 20110317
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Mallinckrodt
McKinsey
Harvard Business School
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.